Effect of novel oral anticoagulants on Hospital Anxiety and Depression Scale scores Auswirkungen neuer oraler Antikoagulanzien auf den Punktwert in der Hospital Anxiety and Depression Scale


Cosansu K., ÜREYEN Ç. M., YILMAZ S.

Herz, cilt.44, sa.8, ss.743-749, 2019 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 44 Sayı: 8
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1007/s00059-019-4828-1
  • Dergi Adı: Herz
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.743-749
  • Anahtar Kelimeler: Atrial fibrillation, Quality of life, Hemorrhage, Warfarin, Non-vitamin K novel oral anticoagulant
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Background: The negative impact of atrial fibrillation (AF) on health-related quality of life has been extensively documented. The aim of this study was to compare the Hospital Anxiety and Depression Scale (HADS) scores of patients with non-valvular AF during warfarin administration and after switching to novel oral anticoagulants (NOACs). Methods: The study comprised 100 consecutive patients on warfarin treatment between July 2018 and January 2019 for whom a transition to NOACs was planned. All patients completed the HADS at the start of the study and at least 3 months after that date. Results: The mean value of HADS-A (5.9 ± 2.1 vs. 4.4 ± 1.6, p < 0.001) and HADS-D (4.4 ± 1.7 vs. 3.7 ± 1.4, p < 0.001) scores was significantly higher in patients when they used warfarin than when they switched to NOACs. Analysis revealed that there was a significant correlation between HADS-A and HADS-D scores with age and history of bleeding (p < 0.001). The highest scores were found for patients with a history of bleeding and age ≥75 years (p < 0.001). Conclusion: Our study demonstrates that patients with nonvalvular AF under treatment with NOACs had lower HADS-A and HADS-D scores compared with patients on warfarin treatment. These findings suggest that NOACs may increase the quality of life and decrease morbidity and mortality by reducing anxiety and depression.